Division of Pharmacological Science, Department of Health Science, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Higashi-ku, Hamamatsu, 431-3192, Japan.
J Physiol Sci. 2019 Nov;69(6):837-849. doi: 10.1007/s12576-019-00721-5. Epub 2019 Oct 29.
We previously reviewed our study of the pharmacological properties of cardiac Na/Ca exchange (NCX1) inhibitors among cardioprotective drugs, such as amiodarone, bepridil, dronedarone, cibenzoline, azimilide, aprindine, and benzyl-oxyphenyl derivatives (Watanabe et al. in J Pharmacol Sci 102:7-16, 2006). Since then we have continued our studies further and found that some cardioprotective drugs are NCX1 stimulators. Cardiac Na/Ca exchange current (I) was stimulated by nicorandil (a hybrid ATP-sensitive K channel opener), pinacidil (a non-selective ATP-sensitive K channel opener), flecainide (an antiarrhythmic drug), and sodium nitroprusside (SNP) (an NO donor). Sildenafil (a phosphodiesterase-5 inhibitor) further increased the pinacidil-induced augmentation of I. In paper, here I review the NCX stimulants that enhance NCX function among the cardioprotective agents we examined such as nicorandil, pinacidil, SNP, sildenafil and flecainide, in addition to atrial natriuretic (ANP) and dofetilide, which were reported by other investigators.
我们之前回顾了我们对心脏 Na/Ca 交换（NCX1）抑制剂在心脏保护药物中的药理学特性的研究，如胺碘酮、贝普地尔、决奈达隆、西苯唑啉、阿齐米德、阿普林定和苯甲氧基苯基衍生物（Watanabe 等人，在 J Pharmacol Sci 102:7-16, 2006）。此后，我们继续进一步研究，发现一些心脏保护药物是 NCX1 刺激剂。心脏 Na/Ca 交换电流（I）被尼可地尔（一种混合 ATP 敏感性 K 通道开放剂）、吡那地尔（一种非选择性 ATP 敏感性 K 通道开放剂）、氟卡尼（一种抗心律失常药物）和硝普钠（一种 NO 供体）刺激。西地那非（一种磷酸二酯酶-5 抑制剂）进一步增加了吡那地尔诱导的 I 增强。在这篇论文中，我回顾了除了心房利钠肽（ANP）和多非利特之外，我们研究的心脏保护剂中增强 NCX 功能的 NCX 刺激剂，如尼可地尔、吡那地尔、硝普钠、西地那非和氟卡尼，这些刺激剂是由其他研究人员报道的。
